<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26578236</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2015</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Interleukin-27 ameliorates coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells.</ArticleTitle><Pagination><StartPage>189</StartPage><MedlinePgn>189</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">189</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-015-0418-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Interleukin (IL)-27, which has both pro and anti- inflammatory properties, is a new discovered heterodimeric cytokine that belongs to IL-12 family. However, the expression pattern and functional role of IL-27 in viral myocarditis (VMC) has not been investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">BALB/c mice were intraperitoneally (i.p) infected with Coxsackie virus B3 (CVB3) for establishing VMC models. Mice were then injected i.p. with Anti-Mouse IL-27 p28Ab or recombinant IL-27 for neutralization and overexpression of IL-27. The survival rates of mice were recorded and the kinetics of IL-27 expression, the frequencies of Th17 cells and the expression of inflammatory cytokine in CVB3-infected mice were determined by ELISA, real-time PCR and flow cytometry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The IL-27 expression in heart tissues and serum in coxsackievirus B3 (CVB3)-induced myocarditis mice peaked on day 4 but then rapidly decreased during the late infectious stage of CVB3, high IL-27 levels were negatively correlated with bodyweight loss (r =&#x2009;-0.71, P = 0.021) and myocardial pathological score (r =&#x2009;-0.85, P = 0.0018). Additionally, neutralization of IL-27 with Anti-IL-27 Ab accelerated, whereas systemic administration of recombinant mouse IL-27 ameliorated CVB3-induced myocarditis. The protective role of IL-27 in VMC was reflected by an improved survival rate, increased bodyweights, and reduced pathological scores in Anti-IL-27 group compared with IgG control group. Mechanistic investigations showed that IL-27 inhibited Th17 cells frequencies and IL-17 production, as well as the Th17-related proinflammatory cytokines in heart tissues.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results demonstrate that that IL-27 effectively protects the myocardium from the pathogenesis of CVB3 induced myocarditis, which may be attributable to reduced Th17 production. IL-27 might serve as a novel therapeutic treatment for VMC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hengshan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Xianyang Hospital of Yan'an University, Xianyang, 712000, Shaanxi, China. redzhu99876@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Chuang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, AnKang Hospital of Traditional Chinese Medicine, Ankang, 725000, Shaanxi, China. louchuan1987606@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xianyang Hospital of Yan'an University, No 38 Wenlin Raod, Xianyang, 712000, Shaanxi, China. Dr_pliu@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064094">Interleukin-27</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064094" MajorTopicYN="N">Interleukin-27</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058504" MajorTopicYN="N">Th17 Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26578236</ArticleId><ArticleId IdType="pmc">PMC4650905</ArticleId><ArticleId IdType="doi">10.1186/s12985-015-0418-x</ArticleId><ArticleId IdType="pii">10.1186/s12985-015-0418-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kuhl U, Schultheiss HP. Viral myocarditis: diagnosis, aetiology and management. Drugs. 2009;69(10):1287&#x2013;302. doi: 10.2165/00003495-200969100-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200969100-00001</ArticleId><ArticleId IdType="pubmed">19583449</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreoletti L, Leveque N, Boulagnon C, Brasselet C, Fornes P. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009;102(6&#x2013;7):559&#x2013;68. doi: 10.1016/j.acvd.2009.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2009.04.010</ArticleId><ArticleId IdType="pubmed">19664576</ArticleId></ArticleIdList></Reference><Reference><Citation>Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus. Circulation. 2009;119(19):2615&#x2013;24. doi: 10.1161/CIRCULATIONAHA.108.766022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.766022</ArticleId><ArticleId IdType="pubmed">19451363</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy J, Massilamany C, Buskiewicz I, Huber SA. Autoimmunity in viral myocarditis. Curr Opin Rheumatol. 2013;25(4):502&#x2013;8. doi: 10.1097/BOR.0b013e3283620036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e3283620036</ArticleId><ArticleId IdType="pubmed">23656709</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D, Stafford KA, Sung YK. Update on coxsackievirus B3 myocarditis. Curr Opin Rheumatol. 2012;24(4):401&#x2013;7. doi: 10.1097/BOR.0b013e328353372d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e328353372d</ArticleId><ArticleId IdType="pmc">PMC4536812</ArticleId><ArticleId IdType="pubmed">22488075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002;16(6):779&#x2013;90. doi: 10.1016/S1074-7613(02)00324-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(02)00324-2</ArticleId><ArticleId IdType="pubmed">12121660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004;172(4):2225&#x2013;31. doi: 10.4049/jimmunol.172.4.2225.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.4.2225</ArticleId><ArticleId IdType="pubmed">14764690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall AO, Silver JS, Hunter CA. The immunobiology of IL-27. Adv Immunol. 2012;115:1&#x2013;44. doi: 10.1016/B978-0-12-394299-9.00001-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-394299-9.00001-1</ArticleId><ArticleId IdType="pubmed">22608254</ArticleId></ArticleIdList></Reference><Reference><Citation>Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matsui M, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol. 2005;175(4):2191&#x2013;200. doi: 10.4049/jimmunol.175.4.2191.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.4.2191</ArticleId><ArticleId IdType="pubmed">16081786</ArticleId></ArticleIdList></Reference><Reference><Citation>Owaki T, Asakawa M, Fukai F, Mizuguchi J, Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol. 2006;177(11):7579&#x2013;87. doi: 10.4049/jimmunol.177.11.7579.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.11.7579</ArticleId><ArticleId IdType="pubmed">17114427</ArticleId></ArticleIdList></Reference><Reference><Citation>Larousserie F, Charlot P, Bardel E, Froger J, Kastelein RA, Devergne O. Differential effects of IL-27 on human B cell subsets. J Immunol. 2006;176(10):5890&#x2013;7. doi: 10.4049/jimmunol.176.10.5890.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.10.5890</ArticleId><ArticleId IdType="pubmed">16670296</ArticleId></ArticleIdList></Reference><Reference><Citation>Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006;7(9):929&#x2013;36. doi: 10.1038/ni1375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1375</ArticleId><ArticleId IdType="pubmed">16906167</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7(9):937&#x2013;45. doi: 10.1038/ni1376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1376</ArticleId><ArticleId IdType="pubmed">16906166</ArticleId></ArticleIdList></Reference><Reference><Citation>Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol. 2007;8(12):1380&#x2013;9. doi: 10.1038/ni1541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1541</ArticleId><ArticleId IdType="pubmed">17994022</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamichi T, Yang J, Huang DW, Brann TW, Fullmer BA, Adelsberger JW, et al. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. Aids. 2008;22(1):39&#x2013;45. doi: 10.1097/QAD.0b013e3282f3356c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e3282f3356c</ArticleId><ArticleId IdType="pubmed">18090390</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakruddin JM, Lempicki RA, Gorelick RJ, Yang J, Adelsberger JW, Garcia-Pineres AJ, et al. Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood. 2007;109(5):1841&#x2013;9. doi: 10.1182/blood-2006-02-001578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-02-001578</ArticleId><ArticleId IdType="pmc">PMC1801045</ArticleId><ArticleId IdType="pubmed">17068156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong Q, Xue Y, Wu W, Yang F, Liu Y, Gao M, et al. IL-22 exacerbates the severity of CVB3-induced acute viral myocarditis in IL-17A-deficient mice. Mol Med Rep. 2013;7(4):1329&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">23426605</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Yue Y, Xiong S. Distinct Th17 inductions contribute to the gender bias in CVB3-induced myocarditis. Cardiovasc Pathol. 2013;22(5):373&#x2013;82. doi: 10.1016/j.carpath.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carpath.2013.02.004</ArticleId><ArticleId IdType="pubmed">23523188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, et al. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol. 2010;185(7):4004&#x2013;10. doi: 10.4049/jimmunol.1001718.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001718</ArticleId><ArticleId IdType="pubmed">20802148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Weifeng W, Yuluan Y, Qing K, Yu P, Yanlan H. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation. Virol J. 2011;8:17. doi: 10.1186/1743-422X-8-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-17</ArticleId><ArticleId IdType="pmc">PMC3032710</ArticleId><ArticleId IdType="pubmed">21235788</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol. 2003;170(10):4886&#x2013;90. doi: 10.4049/jimmunol.170.10.4886.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.10.4886</ArticleId><ArticleId IdType="pubmed">12734330</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Chen R, Zhang X, Chen P, Liu X, Xie Y, et al. The role of Th17 cells and regulatory T cells in Coxsackievirus B3-induced myocarditis. Virology. 2011;421(1):78&#x2013;84. doi: 10.1016/j.virol.2011.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.09.006</ArticleId><ArticleId IdType="pubmed">21993400</ArticleId></ArticleIdList></Reference><Reference><Citation>Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol. 2009;182(9):5748&#x2013;56. doi: 10.4049/jimmunol.0801162.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0801162</ArticleId><ArticleId IdType="pubmed">19380822</ArticleId></ArticleIdList></Reference><Reference><Citation>El-behi M, Ciric B, Yu S, Zhang GX, Fitzgerald DC, Rostami A. Differential effect of IL-27 on developing versus committed Th17 cells. J Immunol. 2009;183(8):4957&#x2013;67. doi: 10.4049/jimmunol.0900735.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900735</ArticleId><ArticleId IdType="pmc">PMC2901918</ArticleId><ArticleId IdType="pubmed">19786534</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>